Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer

GlobeNewswire April 3, 2017

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 31, 2017

Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board

GlobeNewswire March 30, 2017

Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference

GlobeNewswire March 17, 2017

Payor Re-Evaluation On Exondys Positive For Sarepta

Benzinga.com  March 10, 2017

Mid-Morning Market Update: Markets Edge Lower; Big Lots Profit Beats Estimates

Benzinga.com  March 3, 2017

Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference

GlobeNewswire March 2, 2017

25 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 2, 2017

Sarepta Stock Has Fully Consolidated; Leerink Upgrades To Outperform

Benzinga.com  March 2, 2017

25 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 2, 2017

18 Biggest Mid-Day Losers For Wednesday

Benzinga.com  March 1, 2017

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 28, 2017

Ionis Shares Pop As Aetna Adds Spinraza To Precertification List

Benzinga.com  February 28, 2017

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments

Business Wire February 28, 2017

Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M

Business Wire February 21, 2017

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017

Business Wire February 15, 2017

Biotech Stocks on Investors' Radar -- Amicus Therapeutics, Cempra, Ophthotech, and Sarepta Therapeutics

PR Newswire February 10, 2017

The Market In 5 Minutes: Disney, Gilead Investors Not Too Pleased

Benzinga.com  February 8, 2017

Wall Street's M&A Chatter From February 7

Benzinga.com  February 8, 2017

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 31, 2017